Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.07Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: -23.08%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, especially in breast and pancreatic cancers, and a solid financial position with new capital access. However, the ongoing search for a new CEO and a decrease in R&D spending present challenges. The overall sentiment is cautiously optimistic with key strategic advancements underway.Company Guidance
During the recent Oncolytics Biotech conference call, several key metrics and strategic updates were shared. The company reported a cash and cash equivalents position of $15.3 million as of March 31, 2025, with a net cash usage of $6.5 million for operating activities in the quarter. Research and development expenses were $4.1 million, a decrease from $5.7 million in the same quarter of the previous year, attributed to lower manufacturing and clinical trial costs. The net loss for the quarter was $6.7 million, equivalent to $0.08 per share. Oncolytics also announced a $20 million share purchase agreement with Alumni Capital, providing additional financial flexibility. Clinically, the company highlighted ongoing trials of pelareorep, particularly in breast and pancreatic cancer, with promising data shared at various medical conferences. The GOBLET Cohort 5 study, supported by a $5 million PanCAN grant, is advancing with more than half of the necessary participants enrolled. The company is also actively advancing its CEO search and exploring multiple business development opportunities.Progress in Breast Cancer Trials
Two randomized Phase 2 studies showed that pelareorep-based combination therapy substantially outperformed standard care in HR-positive/HER2-negative metastatic breast cancer, with a near doubling of median progression-free survival and two-year survival rate.
Pancreatic Cancer Trial Enrollment
Enrollment for the GOBLET Cohort 5 pancreatic cancer study, funded by a $5 million PanCAN grant, is ongoing with more than half of the Stage 1 patients enrolled.
Financial Runway and Share Purchase Agreement
The company reported $15.3 million in cash and a $20 million share purchase agreement with Alumni Capital, providing financial runway through key milestones and the third quarter of 2025.
Anal Carcinoma Trial Expansion
The GOBLET Cohort 4, investigating pelareorep and atezolizumab in relapsed anal carcinoma, showed a 33% objective response rate, leading to an expansion for Stage 2 enrollment.
ONCY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ONCY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $0.52 | $0.50 | -3.85% |
Mar 07, 2025 | $0.74 | $0.69 | -6.76% |
Nov 12, 2024 | $1.08 | $1.12 | +3.70% |
Aug 01, 2024 | $1.03 | $1.02 | -0.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Oncolytics Biotech (ONCY) report earnings?
Oncolytics Biotech (ONCY) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Oncolytics Biotech (ONCY) earnings time?
Oncolytics Biotech (ONCY) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ONCY EPS forecast?
ONCY EPS forecast for the fiscal quarter 2025 (Q2) is -0.07.